Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.


Options:
A: Men and women hypertensive patients, ages 55 and above. A total of 36 percent were diabetics.
B: Inclusion Criteria:

* patients older than 40 years of age with stage I hypertension

Exclusion Criteria:

* low life expectancy
* other indications for the use of diuretics, such as cardiovascular disease
* intolerance to the study drugs
* pregnancy
C: Inclusion Criteria:

* Hypertensive patients will be 18 to 75-year old.
* Eligible patients will be asked for written informed consent and thereafter referred to the identified Hypertension Specialist Centre located in their areas, for end-organ damage evaluation by echocardiography, carotid ultrasound and urine dip-stick.
* Eligible patients are required to have stage Ic or II essential hypertension, and to be previously untreated or poorly controlled. They will be selected by GPs participating into the study. Similar to untreated patients, those with poor control of blood pressure under multiple-drug therapy will start treatment with one single drug, which will be titrated to the highest dose before adding subsequent medications, based on the GP's judgement.
* Hypertension will be defined according to 2003 ESH/ESC guidelines (1). Blood and urine tests will be performed, according to guidelines for Hypertension Management For General Practitioners (GP) of the Regione Campania (see BURC number 11, 18/02/2002). This screening includes cell blood counts (CBCs), serum creatinine, sodium, potassium, uric acid, total cholesterol, triglycerides, HDL-cholesterol, glucose, urine analysis and EKG. LDL will be calculated starting from the total cholesterol, triglyceride and HDL-cholesterol.

Exclusion Criteria:

* Omen in fertile age not using recognized contraceptive methods, or pregnant or nursing will be excluded from the protocol, since the use of many antihypertensive drugs is contraindicated in pregnancy and lactation.
* Patients will be excluded when presenting with documented coronary or cerebrovascular events in the previous 6 months, NYHA class higher than 1
* History of congestive heart failure
* Secondary hypertension
* Cancer disease
* Renal disease (serum creatinine \>2 mg/dl)
* Liver cirrhosis or severe dysfunction, or any other health problem that may interfere with the projected 2 year follow-up.

Data will be stored in an electronic database located in the Coordinating Centre, to which GPs may have access for uploading data on a daily base, using personal, encrypted, login and password. These data will be stored in the central database. After local echocardiographic evaluation, patients showing left ventricular Ejection Fraction \< 45% will be excluded from the study.
D: Inclusion Criteria:

* Hypertensive patients with diabetes mellitus
* Hypertensive patients
* Hypertensive patients with renal disease

Exclusion Criteria:

* Cardiac, hematologic or hepatic disease
* Renal insufficiency (serum creatinine values\> 2 mg/L)
* Hormone-induced hypertension
* Cerebral infarction or hemorrhage
* Other major diseases

Answer: A